Joelle (@JA_Helou) profile picture

Radiation Oncologist; Department of Oncology; Verspeeteen Family Cancer Centre; Western University, London, ON

Ontario, Canada
Joined October 2016
Photo by Joelle (@JA_Helou)Photo by Joelle (@JA_Helou)Photo by Joelle (@JA_Helou)Photo by Joelle (@JA_Helou)Photo by Joelle (@JA_Helou)Photo by Joelle (@JA_Helou)Photo by Joelle (@JA_Helou)Photo by Joelle (@JA_Helou)Photo by Joelle (@JA_Helou)Photo by Joelle (@JA_Helou)
Can systemic treatment intensification reduce recurrence risk in high-risk localised prostate cancer? #ESMO26 presentation of interim results from the #DASLHiCaP #CCTG PR.22 international (ANZUP 1801) clinical trial. buff.ly/IokpCQt
1
2
201
VOLGA also explored short periods of EV with duvalumab and tremelimumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVDT improved EFS vs cystectomy (HR 0.61). Significant OS was not reached at this interim (HR 0.77 -ongoing analysis). EVDT = 10% higher rates of G3/4 toxicity and less EV delivery than the EV durvalumab arm. More is not always better. It appears the addition of treme partly compromised delivery of EV, which likely accounts for the more modest results compared to the doublet @OncoAlert
41
72
3,777
Rather a brilliant discussion at the presidential #ESMO26 for the DASL very high risk prostate cancer trial The future is patient selection. The clearest indication is in pateints with N1 disease supported by results from thr other trials @OncoAlert @ChrisSweens1 @Uromigos
1
11
44
2,450
With time I think we’ll see an OS!
🚨📣📣 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️ in MFS (HR 0.42) + early OS signal (HR 0.88). #ProstateCancer #RadOnc #pcsm @ChrisSweens1
1
4
690
🚨📣📣 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️ in MFS (HR 0.42) + early OS signal (HR 0.88). #ProstateCancer #RadOnc #pcsm @ChrisSweens1
8
67
10
147
12,998
#ESMO26 Proteus Debate: 1) Are we just seeing the impact of treatment intensification in occult mCSPC? 2) Are we putting mCSPC patients through unnecessary, highly invasive surgery. With severe systemic toxicities and surgical morbidity, how do we justify and weigh the QoL?
1
3
224
Elegant talk by @MattGalsky looking at molecular drivers and subtypes in relation to treatment benefit in #NIAGARA #ESMO26 #Day2 @myESMO @OncoAlert
12
1
19
1,615
What a start for #ESMO26 #Day2 What comes after EV-Pembro ? Excellent overview of sequential systemic therapies in advanced #UC by #DrYohannLoriot @myESMO @OncoAlert
1
14
29
1,937
Joelle retweeted
#ESMO NSABP B-42:The key missing piece? QoL data. How do we balance sustained recurrence prevention against the burden of 10 years of endocrine therapy? #BreastCancer
1
2
175
Perioperative EV + Pembro momentum by #DrAndersUllen in KEYNOTE-905 Ph.III ad hoc analysis of cis-ineligible MIBC. 2-yr EFS: 75.8% EV/Pembro vs 55.8% Pembro vs 41.0% surgery alone. EFS HR 0.40 vs 0.71 (each vs control). pCR 58.8% vs 25.3% vs 10.3%. #ESMO26 #BladderCancer @myESMO @OncoAlert
13
2
16
2,168
#ESMO NSABP B-42:The key missing piece? QoL data. How do we balance sustained recurrence prevention against the burden of 10 years of endocrine therapy? #BreastCancer
1
2
175
#ESMO26: NSABP B-42 at 15 years: extended letrozole continues to improve DFS, with particular relevance for patients with node-positive disease. No statistically significant OS benefit at 15 years, although a trend toward fewer breast cancer deaths is encouraging.
2
7
451
Joelle retweeted
⚠️ Visitors, workers and students in Canada: It is illegal to work in Canada without authorization. In most cases, you need a valid work permit. Learn why it’s important to follow the rules for working in Canada: bit.ly/4qFvI6o
37
33
5
173
260,171
Resident Journal Club | Sept 8 • 12 PM ET OPERA → APHRODITE: Resident‑led look at emerging rectal #brachytherapy evidence & real‑world implementation barriers. Tailored for #residents but open to all physicians & healthcare providers. bit.ly/4niSlLO #radonc
1
3
5
521
Today is world #kidneycancer day! We have made lots of progress but so much work to do! 😃 ikcc.org/world-kidney-cancer… #kcsm @IKCCorg
1
15
37
1,399
Joelle retweeted
✨ What keeps the field's top leaders moving forward? Watch the final part of our interview with Prof Laura Dawson & Prof David Palma as they share what continues to inspire them every day in #radonc. 🎥 Full video below! 👇 #ESTRO26 #Radiotherapy #Inspiration #CancerResearch
3
5
918
If you have 5 minutes give this a listen :)
2
9
1,707
ABS is kicking off 2026 with a deep dive into challenging HDR + LDR #prostate #brachytherapy cases. Our expert panel will walk through patient selection, imaging considerations, and strategies for managing toxicities. bit.ly/4niSlLO #Thisisbrachytherapy #RadOnc #MedEd
1
5
7
1,700
#HRQOL #oligoprog #SBRT 🔥RADIANT - phII oligoprog GI, GU, breast 🔵 secondary outcome - HRQOL ⬇️ mean global health SS but not clinically significant at 6m 🔵disease progression predictor of worse HRQOL on MVA 🔵if no prog HRQOL was stable or improved in 83% 1/
1
7
2
17
6,654
🎉 Congratulations to the 2025–2026 ABS Board of Directors and Officers! Your leadership will shape the future of brachytherapy, and we’re excited for what’s ahead. 💙 @KamravaMD @PeteRossiMD @marisakollmeier #Brachytherapy #ThisisBrachytherapy #BrachytherapyLeadership
5
7
42
1,640